Strides Pharma Science Share: Pros and Cons Every Investor Must Know in 2026

Strides Pharma Science share CMP approx Rs 1,100. 52-week high Rs 1,420, low Rs 680. Market Cap Rs 10,450 Cr. P/E ratio 35.42x.

Is the Strides Pharma Science share a good investment in 2026? This article provides a data-driven analysis of Strides Pharma Science share pros and cons — covering business strengths, valuation, growth drivers, and key risks — based on live data from 7 August 2026.

Click Here — Get Free Investment Predictions

About Strides Pharma Science

Strides Pharma Science Limited (NSE: STAR) is a Bengaluru-based pharmaceutical company founded in 1990 by Arun Kumar. It exports specialty oral dosage formulations — particularly soft gelatin capsules (softgels), controlled release tablets, and complex oral solids — to the US, Australia, UK, South Africa, and other regulated markets. Strides has a complex corporate history involving multiple subsidiaries, stake sales, and restructurings — including the sale of its injectable division (Agila Pharmaceuticals to Mylan in 2013) and various emerging market subsidiary reorganisations.

Key Financial Snapshot: Strides Pharma Science Share

Data approximate. Verify at nseindia.com.

Top 5 Pros of Strides Pharma Science Share

1. Softgel Capsule Specialty — Technical Differentiation in Complex Oral Dosage

Strides Pharma’s specialty in soft gelatin capsule manufacturing provides technical differentiation from standard tablet-only API manufacturers. Softgels are technically challenging to manufacture and have fewer FDA-approved filers than standard tablets — providing better generic pricing durability.

2. US ANDA Pipeline — Specialty Oral Dosage Forms With Better Price Sustainability

Strides Pharma’s US ANDA pipeline focuses on complex oral dosage forms (softgels, controlled release) where fewer generic filers and higher technical barriers provide better pricing sustainability than commodity tablet generics.

3. Australia Market Leadership — Strides is One of Australia’s Largest Generic Suppliers

Strides has strong Australia market presence — one of the largest generic pharmaceutical suppliers to Australian pharmacies. Australia’s regulated generic pharmaceutical market provides stable, predictable revenue from long-term supply agreements.

4. UK and Africa Branded Generic Expansion — International Revenue Diversification

Strides is growing branded generic sales in UK and Africa — adding international branded revenue alongside regulated market commodity generic supply for geographic diversification.

5. Arun Kumar Founder-Promoter Drive — Serial Pharma Entrepreneur Creating Value

Arun Kumar is a serial pharmaceutical entrepreneur who has created significant shareholder value through Strides’ previous divisions (Agila Pharmaceuticals sold to Mylan for Rs 2,500-plus crore). This founder-entrepreneur drive provides strategic initiative in identifying specialty pharmaceutical opportunities.

Key Cons of Strides Pharma Science Share

1. ROE of 12.96 Percent Below Quality Pharma Benchmark — Complex History Depressing Returns

At 12.96 percent ROE with debt-to-equity of 0.47x, Strides Pharma is below quality pharmaceutical benchmarks — reflecting the complexity discount from multiple corporate restructurings, remaining debt from acquisition integration, and the transition period between divested and new pharmaceutical businesses.

2. Complex Corporate History — Multiple Restructurings Creating Investor Confidence Gap

Strides Pharma’s history of subsidiary sales, spin-offs, and restructurings has created a complex corporate narrative that makes institutional investors cautious about long-term strategic consistency. This complexity discount suppresses the PE multiple versus simpler, more focused pharmaceutical peers.

3. US Generic Market Price Erosion — Commodity Oral Solid Competition

Strides’ US ANDA portfolio faces commodity generic price erosion as multiple filers compete in standard tablet and capsule markets. Despite softgel differentiation, standard oral solid products face significant US generic price erosion.

4. 35.42x PE For 12.96 Percent ROE — Valuation Tension Requiring Turnaround Delivery

At 35.42x PE for 12.96 percent ROE, Strides Pharma share is moderately expensive for a company with below-quality return metrics. The PE implies significant ROE improvement delivery through Australia growth, US softgel expansion, and debt reduction.

Use the Univest Screener to Analyse Stocks for Free

Is Strides Pharma Science Share a Good Investment in 2026?

Strides Pharma share is a specialty pharmaceutical export investment with softgel technical differentiation and Australia market strength. Complex corporate history and below-quality ROE are constraints. Consider as small specialised pharma allocation.

Key Risks Before Buying Strides Pharma Science Share

• US generic oral solid pricing deterioration compressing softgel margins along with standard tablets
• Australia generic pharmaceutical market consolidation reducing Strides supply agreements
• Debt-to-equity 0.47x creating financial cost burden in rising interest rate environment
• USFDA warning letter on any Strides facility disrupting US regulated market supply

Conclusion

The Strides Pharma Science share offers softgel capsule specialty — technical differentiation in complex oral dosage as its primary investment case. Weigh it against roe of 12.96 percent below quality pharma benchmark — complex history depressing returns and the risks above before investing. Use the Univest Screener and consult a SEBI-registered advisor.

Download the Univest iOS App or Univest Android App to track Strides Pharma Science share price live.

Frequently Asked Questions — Strides Pharma Science Share

What are the main pros of Strides Pharma share?

Ans. Softgel capsule specialty with technical differentiation from standard tablet pharma, US ANDA pipeline in complex oral dosage with better pricing durability, Australia market leadership with stable supply agreements, UK and Africa branded generic diversification, and Arun Kumar founder-entrepreneur value creation drive.

What are the risks?

Ans. ROE 12.96% below quality pharma benchmark, complex corporate history creating institutional investor confidence gap, US generic price erosion despite softgel differentiation, and 35.42x PE requiring turnaround ROE delivery. Monitor quarterly Australia revenue and US ANDA approval pipeline.

Is Strides Pharma share a good investment?

Ans. Specialty pharma exporter with softgel differentiation at moderate PE. Consider as small specialised pharma allocation. Consult a SEBI-registered advisor. Not investment advice.

What is the 52-week range?

Ans. 52-week high approximately Rs 1,420, low Rs 680. Current Rs 1,100. Verify at nseindia.com.

What are softgel capsules and why is Strides’ softgel manufacturing a differentiator?

Ans. Soft gelatin capsules (softgels) are liquid or semi-solid pharmaceutical formulations enclosed in a gelatine shell — used for drugs that are poorly water-soluble (improved bioavailability in softgel form), oils (fish oil supplements), or where precise liquid dosing is required (Vitamin E, Vitamin D, pain gels). Softgel manufacturing requires specialised encapsulation equipment (Accogel, rotary die encapsulators), strict temperature and humidity control, and different QC compared to standard tablet compression. Fewer pharmaceutical companies have softgel manufacturing capabilities — creating better generic pricing versus standard tablet markets with many filers.

What happened with Agila Pharmaceuticals and how did it impact Strides?

Ans. Agila Pharmaceuticals was Strides’ injectable pharmaceutical subsidiary — one of India’s largest sterile injectable manufacturers. Strides sold Agila to Mylan (now Viatris) in 2013 for approximately Rs 2,500-plus crore — one of the largest Indian pharmaceutical transactions. The sale generated significant cash that Strides used for other acquisitions and debt reduction. However, post-Agila, Strides needed to rebuild its pharmaceutical business around the remaining oral dosage and regulated market operations — leading to the multiple restructurings that created the complex corporate history investors now discount.